Drugs / NoV Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03039790 | Feb 2017 → Jul 2021 | norovirus infectious disease | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NoV vaccine | “The drug being tested in this study is called NoV vaccine.” NCT03039790 ↗ |
| Modality | Vaccine | “NoV vaccine is being tested for protection against acute gastroenteritis (AGE) due to norovirus.” NCT03039790 ↗ |
| Route | Intramuscular | “Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminium hydroxide, IM, on Day 1 and Day 28” NCT03039790 ↗ |